Alzheimer's Disease Risk & Cognitive Decline Panel
Early detection of Alzheimer's disease is possible years before symptoms begin. Our comprehensive panel combines genetic, molecular, and biomarker analysis with reversible cause screening — empowering you and your clinician to take proactive steps against cognitive decline.
Understand Your Genetic Risk-
APOE Genotype
- ε4 allele increases risk of late-onset Alzheimer's disease.
- Helps with risk stratification and personalized counseling.
- Not deterministic — lifestyle and environment play key roles.
Detect Early Changes with the ATN Framework
A (Amyloid)
Aβ42, Aβ40, Aβ42/40 ratio
Low ratio indicates amyloid accumulation
T (Tau)
p-tau181 (or p-tau217/p-tau231)
Elevated levels signal Alzheimer's-specific pathology.
N (Neurodegeneration)
Neurofilament Light Chain (NfL), MRI volumetrics, FDG-PET
Indicates neuronal injury and structural loss.
Rule Out Treatable Causes of Cognitive Decline
Thyroid
-
TSH – screens
for hypothyroidism
Infectious
-
RPR –
syphilis
-
Lyme antibody
panel
-
ANA –
autoimmune causes
Nutritional / Metabolic
-
Vitamin
B12
-
MMA –
functional B12 deficiency
-
ESR –
inflammation marker
Clinical Utility
How This Panel Helps You
-
Baseline risk assessment (APOE +
ATN)
-
Identify treatable causes
-
Guide personalized prevention
strategies
-
Inform clinical trial eligibility